Skip to content

Efficacy and Safety Study of Aspirin for the Prevention of Renal Artery Stenosis in Renal Transplantation Recipients

Efficacy and Safety Study of Aspirin for the Prevention of Renal Artery Stenosis in Renal Transplantation Recipients

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04260828
Enrollment
368
Registered
2020-02-07
Start date
2020-02-28
Completion date
2022-12-31
Last updated
2020-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Transplant

Brief summary

The anastomotic and peripheral stenosis of the transplanted kidney artery is one of the most important causes of graft failure in renal transplantation. The injury of vascular intima and the formation of microthrombosis may play a significant role in the stenosis of transplanted renal artery of recipients. Inhibiting this process with aspirin may protects against the stenosis of transplanted renal artery. This is a prospective, randomized, controlled, clinical trial to investigate the efficacy and safety of prevention of renal artery stenosis in recipients.

Interventions

Daily active drug administered orally for 3 months.

OTHERPlacebo

Sugar pill administered orally for 3 months.

Sponsors

Henan Provincial People's Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. The patients with the first renal transplantation were stable; 2. Age ≥ 18 years old; 3. Other anticoagulants and non steroidal anti-inflammatory drugs were not taken at the same time; 4. In the past 3 months, there was no acute cardiovascular and cerebrovascular disease or infection; 5. The rejection of acute and chronic renal transplantation was excluded; 6. The thrombus formation of transplanted kidney was excluded.

Exclusion criteria

1. Allergic or intolerable to aspirin; 2. Previous transplant history; 3. Age \< 18; 4. Take other anticoagulants or non steroidal anti-inflammatory drugs at the same time; 5. History of active gastrointestinal bleeding or severe peptic ulcer; 6. Patients with bleeding tendency or severe liver disease; 7. Cerebral hemorrhage, cerebral infarction or acute infection occurred within 3 months; 8. Acute and chronic rejection; 9. Thrombus formation of transplanted renal vessels; 10. Any condition that increases the risk of adverse events or discontinuation.

Design outcomes

Primary

MeasureTime frameDescription
Incidence of Renal Artery Stenosis2 yearsRenal artery stenosis is defined as the presence of post-transplant renal artery stenosis in recipients evaluated by ultrasonography or renal arteriography.

Secondary

MeasureTime frameDescription
Renal Allograft Function2 yearsRenal allograft function is evaluated by mean estimated glomerular filtration rate(eGFR).
Incidence of Graft Loss2 yearsThe incidence of kidney failure within 2 years of transplant.

Countries

China

Contacts

Primary ContactXiangyong Tian
tianxiangyong888@163.com+86-15333818352
Backup ContactTianzhong Yan
ytz460@hotmail.com+86-13663718703

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026